CGIM
HZNP

Cannon Global Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cannon Global Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,000
Closed -$1.5M – 44
2023
Q3 		$1.5M Sell
13,000
-500
-4% -$53.7K 10.5% 1
2023
Q2 		$1.39M Buy
+13,500
New +$1.42M 7.22% 3
2022
Q1 		– Sell
-8,000
Closed -$862K – 118
2021
Q4 		$862K Buy
8,000
+3,000
+60% +$327K 1.36% 14
2021
Q3 		$548K Buy
+5,000
New +$519K 0.82% 30

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cannon Global Investment Management's HZNP Position: Q4 2023 in Review

Cannon Global Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 13,000 shares — an estimated $1.5M sold.

Cannon Global Investment Management first reported a position in HZNP in Q3 2021 and held it in 4 quarters. The position peaked at $1.5M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Cannon Global Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Cannon Global Investment Management sold 13,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.5M.
  • Cannon Global Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 4 quarters.
  • Cannon Global Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.5M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Cannon Global Investment Management's 13F filing for Q4 2023, filed 31 Jan 2024.